| GURUGRAM, India, June 16, 2022 /PRNewswire/ — Ecom Express Limited, one of India’s leading technology enabled end-to-end logistics solutions providers to the e-commerce industry, has been featured as ‘One of the Best Workplaces in Transportation & Logistics’ by the Great Place to Work® Institute. This recognition is based on rigorous assessment and is an acknowledgement of the company’s High-Trust, High-Performance Culture™. Great Place to Work® Certification is recognised world over by employees and employers alike and is considered the ‘Gold Standard’ in identifying and recognising Great Workplace Cultures.
Being featured among India’s Top 6 Best Workplaces in Transportation & Logistics 2022 is a celebration of the company’s stand in the industry, the exceptional working environment and culture that support employee well-being, safety, and learning, while enhancing employee engagement and pride within the organisation. Commenting on this accomplishment, T. A. Krishnan, Chief Executive Officer & Co-Founder, Ecom Express Limited, said, “To be recognised among the Best Workplaces in Transportation and Logistics is a testament to the strong employee-centric culture of Ecom Express. For a company of 50,000+ employees operating in more than 2700+ cities and towns, this is phenomenal. Being considered as one of the best places to work is the result of a sustained focus on jointly building an environment that motivates, values, and develops our people. We foster an inclusive, equitable, and welcoming environment where people can be themselves and put themselves out there because ultimately that allows them to try new things and take risks. I congratulate each of my colleagues for this milestone.” Over the last nine years, the organisation has deeply infused diversity and inclusion in its culture so employees have an equal chance to excel in their careers. Ecom Express truly believes in the voice of its people getting heard, acknowledged, and actioned upon to enhance employee experiences and empower them to achieve their business goals. Saurabh Deep Singla, Chief People Officer, Ecom Express Limited, said, “We are honoured to be recognised among India’s Best Workplaces in Transportation & Logistics 2022. The recognition reflects the organisation’s and our people’s commitment to the effort of making a great workplace for all. Our team who spreads smiles across the nation through e-commerce order deliveries are our biggest asset and their engagement and motivation are the prerequisite for our on-going success. We will continue to keep our colleague’s trust and foster on providing better working experience. This helps us innovate better with some powerful ideas and business solutions coming from diverse backgrounds” In India, the Great Place to Work® Institute partners with more than 1100 organisations annually across over 22 industries to help them build High-Trust, High-Performance Cultures™ designed to deliver sustained business results. Hundreds of CEOs and CXOs from India Inc. are part of the great place community that is committed to the vision of making India a great place to work FOR ALL™. The Great Place to Work® ranking for Ecom Express can be found here. Ecom Express is truly a place for employees to grow and scale new heights. Be a part of the movement. About Ecom Express: Ecom Express Limited is one of India’s leading end-to-end technology enabled logistics solutions providers to the Indian e-commerce industry. Headquartered in Gurugram, Ecom Express was incorporated in 2012 by T.A. Krishnan, Manju Dhawan, K. Satyanarayana and late Sanjeev Saxena with their 100+ years of cumulative experience in the Indian logistics and distribution industry. Ecom Express has its presence in all 28 states of the country and operates across 27,000+ PIN codes in India. Through its deep reach strategy, the company has the capability to deliver to 95%+ of India’s population. For more information, please visit: https://ecomexpress.in/ Photo: https://mma.prnewswire.com/media/1841389/Ecom_Express_Employees.jpg (Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same) |
Month: June 2022
DS Group Launches a Water Economic Zone in Madhya Pradesh
Creation of Water Economic project in Khandwa and Betul
DS (Dharampal Satyapal) Group announced the launch of the second ‘Water Economic Zone’, an integrated watershed development project at Khandwa and Betul districts in Madhya Pradesh, after successfully implementing the first programme at Alsigarh and Kurabad Watershed areas in Udaipur. The proposed intervention will be implemented in 3000 ha. Area of Barud Gram Panchayat in Chhaigaon Makhan block of Khandwa district and 2400 ha. Area of Dabhona Gram Panchayat in Athner block of Betul district and will reach out to more than 2000 households, mostly from marginalized section of the society.
 |
A community pond constructed by DS Group in Chhatarpur, Madhya Pradesh
‘Creation of Water Economic Zone’, through integrated watershed development projects focus on enhancing natural resources, particularly water and soil of an area, to increase its productivity. These project involve construction of recharging and storage structures, renovation of existing defunct or underutilized water bodies, soil conservation measures, introduction of efficient irrigation practices and also building institutions for long-term sustainability. The availability of water at surface and sub- surface level is enhanced many fold due to the watershed structures, which leads to increased irrigated area and improved crop productivity resulting in better economic conditions of the communities in the intervention areas. The project also promotes efficient use of water through improved irrigation practices such as Drip Irrigation and Rain guns along with harvesting climate-friendly crops.
The company has partnered with grass root level organizations – Arpan Seva Sansthan and Haritika for the implementation of the project in these two districts. A detailed project report (DPR) based on net planning under preparation for construction of various water conservation measures such as check dams, renovation of existing structures, de-siltation of ponds, Soil conservation measures such as CCT, DCCT, gabion for implemented in next few years.
To ensure long term sustainability, the company empowers the local communities and create community institutions like water users groups, farmers’ collectives, or any other suitable community institutions that successfully maintain and ensure continuity of the intervention.
DS Group launched the first ‘Water Economic Zone’ in the Alsigarh and Kurabad Watershed areas in Udaipur (Rajasthan) in 2018. The project reaches out to more than 23000 people from 26 villages, mostly from a tribal background, and will cover an area of around 11000 hectares across both locations in Udaipur by next year.
The project area had low productivity rain-fed farming, severe soil erosion in the undulating topography and degraded land and forest. Currently, the project is being implemented in an area of 9214 Hectares (4984 Hectares in Alsigarh and 4230 Hectares in Kurabad). DS Group has constructed 311 soil and water conservation structures such as Anicuts or Check Dams, Mini Percolation Tanks or Earthen Dams, and other structures like Continuous Contour Trenches, Gabion, Gully Plugs, Recharge Pits, etc. These structures have a water storage and recharge capacity of about 21, 52,931 Cubic meters. 1,26,860 cubic meters of Continuous Contour trenches have been constructed so far, which can recharge 7,04,960 cubic meters of water in an average monsoon. Additional 456 ha area has been brought under irrigation with these efforts.
DS Group also supported construction & rejuvenation of three Community Ponds in Chhatarpur district to enhance groundwater levels through recharge and restoration and also promote water-efficient farming practices. The project benefits around 2000 marginalized population, whose main source of livelihood is agriculture and cattle rearing. A Stop Dam at Gopalpura village of Meghnagar block in Jhabua district, Madhya Pradesh was also constructed by the Group, which has benefited around 200 families, whose livelihood depends on agriculture. Potable water has also been made available for them.
The Group is also supporting Adharshila Shiksha Samiti to run a Sr. Secondary School for Sahariya Tribes in a remote part of Sheopur district in Madhya Pradesh. The school is providing quality education and preparing around 500 students for higher education. The school was started to empower the next generation of tribal communities that were resettled outside the Kuno Wild Life Sanctuary.
The DS Group aims to ensure long term availability of water through geography specific conservation measures and judicial utilization of resources. The group supports multiple projects in partnership with like-minded grassroots level organizations in the state of Rajasthan, Madhya Pradesh, Uttar Pradesh, Himachal Pradesh, Uttarakhand and Gujarat, benefitting millions of people from the marginalized communities. Recognizing the efforts of the organization towards making India Water Secure, it was recently awarded third best Industry for CSR activities at National Water Awards organized by Ministry of Jal Shakti, Government of India.
View article…
(Disclaimer: The above press release comes to you under an arrangement with NewsVoir India and this publication takes no editorial responsibility for the same)
Star Air launches direct flight between Bidar and Bengaluru
BENGALURU and KOLHAPUR, India, June 15, 2022 /PRNewswire/ — With an ardent effort to strengthen Karnataka’s regional connectivity, Ghodawat Enterprises Pvt Ltd operating under the brand name Star Air is set to launch its new regional destination Bidar from Bengaluru. The non-stop flight will begin operations w.e.f 15th June 2022 and will be its 18th destination.
With only limited flights flying to the architectural and religious city of Bidar, Star Air is proud to have the honor of flying passengers to the ‘City of Whispering Monuments.’ Famous for its Bidri handicrafts, rich history, and religious significance to the Sikh community, Bidar has transformed itself into a confluence of urban development and cultural heritage. With this launch, Star Air will operate its Embraer 145 jets to the cool and picturesque hills of Bidar, making it the perfect destination for a getaway holiday. As air connectivity is both an economic enabler as well as an employment growth engine, flights to the new destination will not only strengthen tourism, but also boost the socio-economic growth of the city.
As the launch to Bidar marks itself as a symbol of better connectivity and networking, Mr. Shrenik Ghodawat, MD – Star Air, said, “We are pleased to announce Bidar as our 18th destination. The launch of Bidar to Bengaluru would enable business and leisure travel growth between these cities. As we intend to provide the easy access of flying to the common man, we are also proud to contribute to the growth of the regional destinations we fly to. We hope to continue connecting our loyal passengers to many other regional and picturesque cities of India in the times to come.”
Star Air will operate four times a week between Bidar and Bengaluru on Monday, Wednesday, Friday, and Sunday. The schedule of these flights has been planned to offer passengers the most reasonable prices under the popular UDAN scheme.
The flight service between Bengaluru and Bidar covers 520km of this distance in just 1 hour 10 minutes instead of 8-12 hours via other modes of transportation. Tourists can also visit Kalaburagi, Nanded, Nizamabad, and Hyderabad as they lie in close proximity to Bidar.
Currently, Star Air offers scheduled flight services to 18 Indian destinations that include Ahmedabad, Ajmer (Kishangarh), Bengaluru, Belagavi, Delhi (Hindon), Hubballi, Indore, Jodhpur, Kalaburagi, Mumbai, Nashik, Surat, Tirupati, Jamnagar, Hyderabad, Nagpur, Bhuj, and Bidar. For more information, please visit www.starair.in. One can also connect with Star Air on Facebook, Twitter, and Instagram.
About Sanjay Ghodawat Group
Sanjay Ghodawat Group (SGG) is a prominent Indian business conglomerate that has a presence in various high-value business verticals. Aviation, Consumer Products, Education, Energy, Mining, Realty, Retail, and Textiles are some of its key business domains. SGG was founded in 1993 and since then it has witnessed impressive growth under the splendid stewardship of its Founder and Chairman- Mr. Sanjay Ghodawat. It has a strong base of millions of customers globally, an employee strength of over 10,000, and a student base of over 16,000. SGG is moving ahead with great vigour and bringing significant changes in people’s lives with its wide range of high-quality products and services.
For more information, please visit www.ghodawat.com
Photo: https://mma.prnewswire.com/media/1840214/Star_Air_New_Destination.jpg
Logo: https://mma.prnewswire.com/media/1734796/Star_Air_Logo.jpg
(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same)
Avanse Financial Services partners with National Skill Development Corporation to enable financial solutions for skill development for the youth
Partnership to fulfil skilling requirements of 8-10 lakhs aspirants in the next 5 years
Avanse Financial Services, India’s new age, technologically advanced education-focused NBFC, partnered with the National Skill Development Corporation (NSDC) to provide easy, fast, and affordable financing solutions for the youth of the country interested in fulfilling their skilling requirements. This collaboration is a progressive step towards catering to the growing need for a skilled workforce in the country across various sectors by assisting the aspirants in acquiring the required skills with the help of customised financing solutions.
Skill-based education or vocational training is extremely crucial as employers expect potential employees to have practical skills and the required expertise along with academic degrees. Technical and Vocational Education & Training (TVET) enables people to acquire the necessary skills, which makes them job-ready and thus, positively impacts the economy in the long-run. This unique partnership will assist Avanse Financial Services in creating an empowered workforce in India with the help of the institutions affiliated with NSDC through a result-oriented framework that corresponds with the need of the industry.
On the commencement of this collaboration, Mr. Amit Gainda, MD & CEO, Avanse Financial Services said, “Skill development is extremely crucial, as it can contribute to structural transformation and economic growth by enhancing employability and labour productivity. India is one of the youngest countries in the world, with more than 62% of the population in the working-age group and more than 54% of the total population below 25 years of age. This creates a large pool of human resources with high-untapped potential for development.”
He further said, “We are delighted to partner with NSDC as it will give us an impeccable opportunity to strengthen our purpose of democratising education and education financing in India. This will enable us to contribute towards developing a ‘skilled India’, a nation with a future-ready young population geared up to reach the zenith of success. We believe this partnership will enable us to amplify our reach and thus, fulfil our mission of making education financing seamless, affordable and accessible for every deserving Indian student.”
Mr. Ved Mani Tiwari, COO and Officiating CEO, NSDC stated, “Access to finance is critical for democratisation of education and skills. Partnerships with NBFCs like Avanse Financial Services help NSDC move one step closer towards its core purpose, ‘Skills4All, Anytime, Anywhere’, as it helps achieve financial inclusion of those sections of our society who otherwise can’t imagine acquiring skills for new age employment/entrepreneurship opportunities in India or overseas.”
Avanse Financial Services has fulfilled the educational dreams of ~2.5 lacs academic aspirants across 3,000+ institutes and 22,000+ courses in ~50 countries. The firm has also provided growth and working capital to ~1K educational institutes catering to over ~5-6 lacs students.
Sputnik V demonstrates 97% efficacy against hospitalisation caused by Omicron variant following revaccination with Sputnik Light or Sputnik V according to a study published in the Vaccines peer-reviewed leading medical journal,,
The Gamaleya National Research Center of Epidemiology and Microbiology (Gamaleya Center) today announced that Vaccines, the leading peer-reviewed medical journal, has published the results of a joint study conducted by team of scientists including representatives of Moscow’s City Clinical Hospital No. 67 named after L.A. Vorokhobov and the Gamaleya Center showing the two-dose Sputnik V vaccine is 97% effective against hospitalisation caused by the Omicron variant of coronavirus (B.1.1.529) among those vaccinated with 3 or 4 components (re-vaccination with Sputnik Light or Sputnik V after Sputnik V).The corresponding article has been peer-reviewed and is available at:
https://www.mdpi.com/2076-393X/10/6/938/htm
The study was conducted from 11 January to 21 February 2022 involving over 1,000 patients in Moscow. Sputnik V showed high efficacy against hospitalisation at 85.9% among patients vaccinated with at least one component. Efficacy among those vaccinated with 3 or 4 components (re-vaccination with Sputnik Light or Sputnik V after Sputnik V) rose to:
- 97% against any cases of hospitalisation;
- 97.7% against moderate-severe and more severe cases;
- 98.6% against severe and critical cases;
- 99.4% against critical cases.
As authors note, “the study shows that vaccination with Sputnik V and Sputnik Light has a high effectiveness for protection against hospitalisation. The reduction in the severity of COVID-19 regarding the Omicron variant was also observed. The greatest effectiveness was evident in protection against a critical course of the disease requiring patients to be admitted to the intensive care unit.”
To date, Sputnik V has been authorized in 71 countries with a total population of over 4 billion people, and Sputnik Light has been approved in more than 30 countries. The Russian Direct Investment Fund invested in development and production of both Sputnik V and Sputnik Light.
Cyril Amarchand Mangaldas Advises in Relation to the IPO of Delhivery Limited
Cyril Amarchand Mangaldas advised the book running lead managers, namely, Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, BofA Securities India Limited, and Citigroup Global Markets India Private Limited (“BRLMs”) in relation to the initial public offer of equity shares of Delhivery Limited (“Delhivery”) aggregating to INR 52,350 million (the “Offer”).
Delhivery is the largest and fastest growing fully integrated logistics player in India (in terms of revenue for Fiscal 2021), and provides a full-range of logistics services. Delhivery operates a high-quality logistics infrastructure, working with a vast network of domestic and global partners.
The Capital Markets team of Cyril Amarchand Mangaldas was led by Yash Ashar, Partner & Head – Capital Markets; Gokul Rajan, Partner; with support from Nayan Jain, Principal Associate; Aniran Ghoshal, Senior Associate; along with Jhalak Shah, Associate; and Avinash Gautam, Associate.
The Offer comprised a fresh issue of 82,152,503 equity shares of Delhivery aggregating to INR 40,000 million and an offer for sale of 25,364,585 equity shares of Delhivery aggregating to INR 12,350 million, for cash at a price of INR 487 per equity share. The Offer also included a reservation of 432,900 equity shares aggregating to INR 200 million for eligible employees and a discount of INR 25 per equity share was offered to eligible employees.
Other Parties and Advisers to the transaction included Linklaters Singapore Pte. Ltd. (acted as International legal advisers to the BRLMs); Latham & Watkins LLP (acted as International legal advisers to Delhivery); and Morrison and Foerster LLP (acted as International legal advisers to the SVF Doorbell (Cayman) Ltd).
The equity shares of Delhivery were listed on the stock exchanges on May 24, 2022.
(Disclaimer: The above press release comes to you under an arrangement with NewsVoir India and this publication takes no editorial responsibility for the same)
Money View Announces Multiple ESOP Buybacks
| BENGALURU, India, June 15, 2022 /PRNewswire/ — Bengaluru headquartered Fintech platform, Money View, has announced its first ESOP buyback for its employees. With Money View’s profits growing tremendously over the last 18 months, the company has decided to reward the employees with this ESOP buyback.
The company has initiated a buyback in June’22 where all the existing employees who have completed one year with Money View will be eligible to participate and sell upto 20% of their vested shares in this buyback. The company also plans another buyback by June 2023 with more to follow. With positive unit economics for the last four years, and company-level profitability growing over the last 1.5 years, Money View has taken various initiatives to reward its employees in the past as well. In October last year, the company had announced an early appraisal for all its employees along with additional cash bonuses. Money View with tremendous growth and product expansion plans, aims to hire 600 employees across Tech, Product & Analytics roles among other areas. Puneet Agarwal, Co-Founder and CEO, said, “We’re amongst very few startups who’re growing profitably. This has only been possible because of the collective conviction and the contribution of the entire team. With this buyback programme, we are celebrating and acknowledging the hard work and passion of our colleagues.” Money View has been growing 4x year-over-year, and is on a trajectory to reach more than $1 billion AUM by the end of the year. About Money View: Founded in 2014, Money View aims to provide access to world class financial products to every Indian with a Smartphone and a Bank Account through a suite of financial products backed by Data and Tech. Money View is a series-D funded company with Tier-1 investors like Tiger Global, Accel Partners, Ribbit Capital, Evolvence India, Winter Capital Partners amongst others. Logo: https://mma.prnewswire.com/media/1762976/Money_View_Logo.jpg (Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same) |
Genes2Me Launches CoviEasy® “At-Home” Self-Test Kit for COVID-19
Genes2Me Pvt. Ltd., one of the leading IVD solution manufacturer of India, is elated to announce the launch of its CoviEasy Self-Test Rapid Antigen test kit for COVID-19 that is easy to use and give faster results in 10 minutes. Backed by AI driven Mobile App, this IVD product delivers high level of sensitivity and concordance of more than 98% accuracy.
 |
CoviEasy: COVID-19 Rapid Antigen Self Test by Genes2Me
CoviEasy has undergone stringent quality checks at ICMR approved Validation center and further received approval from CDSCO India. CoviEasy test can be easily performed by following simple instructions provided on the Mobile App (which is available on both Android and iOS platforms) leading to Automated Reporting of test results from this Mobile App itself.
The CoviEasy test involves couple of easy and simple steps as is conducted with a nasal swab sampling, wherein the swab first need to be inserted in the nostrils. The swab needs to be dipped in the buffer tube and swirl 8-10 times in the extraction buffer. The Buffer is then dropped onto the CoviEeasy test device which shows test result as either positive or negative. The test device also comes with a unique QR code for unique patient data entry and accurate report generation.
Mr. Neeraj Gupta, the Founder and CEO of Genes2Me Pvt. Ltd. while commenting on the launch of product said, “Now that many of us are opting for “At-home” test kits as our first line of defense against COVID, “Accuracy” becomes non-negotiable/most Important factor. We understood the need of the hour and came up with a test kit which is more than 98% accurate. Our Covieasy kit will provide almost the assurances of RTPCR with the convenience of “at-home” self-test kit. We plan to help the society with India’s most accurate kit and meet the requirement with our advanced manufacturing unit.”
About Genes2Me Pvt. Ltd.
Genes2Me Pvt. Ltd., founded in 2016, is now one of India’s leading companies in the field of IVD Kit manufacturing and molecular diagnostics. Genes2Me has State-of-Art manufacturing facility for IVD kits and has worked tirelessly to provide people with high-quality IVD Kits and Point of care solutions for last so many years. It has provided lot of premium quality IVD solutions for COVID-19 such as Real-time PCR Kits, RNA Extraction Kits, Rapid Tests, Next-Generation Sequencing (NGS) Kits and Multiplexed Genotyping assays. These IVD kits have demonstrated accuracy, sensitivity, and specificity, as well as the ability to deliver faster results.
All Genes2Me products listed above are by Genes2Me Private Limited.
For more information, please visit www.genes2me.com.
(Disclaimer: The above press release comes to you under an arrangement with NewsVoir India and this publication takes no editorial responsibility for the same)
Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia
- In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19).
- The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in patients with severe COVID-19 pneumonia.
- Results from the Phase 2 trial were presented at the American Thoracic Society (ATS) 2022 International Conference and published in Infectious Diseases and Therapy
MILAN, June 13, 2022 /PRNewswire/ — Dompé farmaceutici S.p.A (“Dompé”) today announced results from its Phase 2 clinical trial demonstrating that, in patients in severe COVID-19 Pneumonia, Reparixin led to an improvement in clinical outcomes when compared with the standard of care, a larger phase 3 clinical study is needed to confirm these results. Results from the Phase 2 trial are published in Infectious Diseases and Therapy and were presented at the scientific sessions of the ATS 2022 International Conference in San Francisco, California.
Acute lung injury and acute respiratory distress syndrome (ARDS) are common complications in patients with COVID-19.1 As part of its commitment to invest in research for unmet medical needs, Dompé conducted an open-label, multi-center study to evaluate the inhibition of IL-8 which is known to be associated with cytokine release syndrome connected to Covid-19 disease.
“Reparixin is a new investigational molecule that seems to have a novel application in patients with acute respiratory inflammation induced by COVID-19. It was well tolerated in clinical studies,” said Giovanni Landoni, MD, Director of CARE (Center for Intensive Care and Anesthesiology) at Hospital San Raffaele in Milan, Italy. “The outcomes as compared to the standard of care may now be reduced by the widespread use of COVID-19 vaccines, but the obtained results indicated continued investigation would be valuable in patients with acute respiratory inflammation.”
Fifty-five patients were randomized 2:1 to receive 1200 mg of oral Reparixin, an inhibitor of IL-8, three times daily or the standard of care for up to 21 days. The rate of clinical events was statistically significantly lower in the Reparixin group compared to those assigned to the group receiving standard of care (27% vs. 42.1%, p=0.02). Treatment with Reparixin was well-tolerated in terms of treatment-emergent adverse events, laboratory test and vital sign parameters2.
“Dompé, along with the rest of the biopharmaceutical world, has worked with urgency to fight COVID-19 and its complications,” said Flavio Mantelli, Chief Medical Officer at Dompé. “While vaccines have helped to mitigate severity of disease, in-hospital treatment options for those who are most seriously impacted remain limited. We are dedicated to this patient population, we are looking forward to continuing our clinical development program to evaluate the potential to reduce COVID-19 respiratory complications.”
About the Study3
The study was an open-label, multicenter, randomized, phase 2 clinical trial designed to assess the efficacy and safety of oral Reparixin in adult patients hospitalized with severe COVID-19 pneumonia from May 5, 2020, until November 27, 2020 and now released for the first time. The study enrolled 55 adults (aged 18–90 years old) hospitalized with severe COVID-19 pneumonia, assigned randomly 2:1 to receive 1200mg Reparixin orally three times daily or standard of care (SOC) for up to 21 days. At least one treatment emergent adverse event occurred in 3 patients in the Reparixin group, and 5 patients in SOC. Reparixin overall appeared to be well tolerated.
All patients received the standard care based on their clinical need, including COVID-19 medications, as per local standard therapy at the trial site hospital and in line with international guidelines.
Please refer to NCT04794803 for additional clinical trial details.
About Dompé
Dompé is a privately-held biopharmaceutical company founded in Milan, Italy, with a 130-year legacy of R&D and medical innovation. Today, Dompé, with Headquarters in Milan, employs more than 800 employees worldwide, with a commercial operations hub in the San Francisco Bay Area, U.S.
Forward Looking Statements
This press release refers to certain information that may not coincide with expected future results. Dompé firmly believes in the soundness and reasonableness of the concepts expressed. However, some of the information is subject to a certain degree of indetermination in relation to its research and development activities and the necessary verifications to be performed by regulatory bodies. Therefore, as of today, Dompé cannot guarantee that the expected results will be consistent with the information provided above.
References
1. Tzotzos SJ, et al. Crit Care. 2020 Aug 21;24(1).
2. A phase 2 multicenter, randomized, controlled study to evaluate the efficacy and safety of Reparixin in hospitalized adult patients with COVID-19 pneumonia, ATS 2022 International Conference in San Francisco, California.
3. https://www.springer.com/journal/40121
Photo – https://mma.prnewswire.com/media/1837356/Dompe_Farmaceutici.jpg
Logo – https://mma.prnewswire.com/media/1837355/Dompe_Farmaceutici_Logo.jpg
(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same)
Janhit Mein Jaari is here to Break Taboos of the Indian Society says Director Jai Basantu Singh
Gone are the days when directors would vie for big budget projects, popular starcast, larger than life storyline. These days a socially relevant film that entertains while passing a message to the society is exciting enough. That’s precisely how debutant Director Jai Basantu Singh feels about his maiden venture Janhit Mein Jaari. “I really couldn’t have found a better project to kickstart my directorial journey,” says Singh.
 |
Director Jai Basantu Singh
t wouldn’t be wrong to say that Jai Basantu Singh’s journey to film industry was predestined. His mother was a huge film buff, and he grew up amidst film shoots and film screenings. “My mother was total film buff and would watch all films first day first show. She would take me to watch a lot of films also. That’s where I picked up the love for cinema. I grew up in Goregaon, Mumbai. That’s where most of the film studios are located. I still remember, I would bunk school and go and watch shootings on the sets for hours. I knew even then; this is the industry I wanted to get in. I wanted to be the man, the name called director. While many of my friends would be interested in watching the actors, I used to be fascinated by this person who would call the shots. The one everyone would listen to and follow. I didn’t know what a director was but I knew back then too, this is who I wanted to be. This was my dream in watching the person in my childhood,” says Singh with certainty.
Janhit Mein Jaari didn’t just fall in Singh’s lap. There were long, struggle some years before getting his chance to helm a full length feature film. Singh recalls his journey and says, “When I entered the industry, I went straight into production and it didn’t take much time for me to realise that direction was my true calling. I worked as an assistant director for 3-4 years and then joined Zee TV as campaign and promo director. I shot 600-700 campaigns and promos of fiction and reality shows. That’s where my journey into direction began. My boss then, Puneet Goenka and Ashwini Yardi really gave me a free hand to shoot the way I wanted. I would really owe a great deal of my learning years to Zee Tv and both of them. In 2008 I quit Zee and went onto independently direct campaigns and promos of almost all big broadcasters. In 2009 recession came and that’s when i started directing TV shows as set up director where my journey of telling a story from 30 sec to 30 min began. I owe a great deal of my journey upto this point to television shows. I couldn’t be where I am today if it weren’t for all the campaigns and TV shows I directed.”
Singh directed many popular and successful shows like Ye Un Dino Ki Baat Hai, Ek Duje Ke Vaste, Ye Pyaar Nahi To Kya Hai, Ye Rishta Kya Kehlata Hai, Namune, Jeannie Aur Jiju many hit shows.
I came on this project as Screenplay writer but wherever I used to narrate the script be it to actors, studios, or producers they always acknowledged of how effortlessly I narrate without even looking at the script even once that too for straight two and half hours. That is when my team, producers and studios started telling me that I should direct the film. Seeing the faith people had in me, I got the strength to direct this film.
He further adds, “Janhit Mein Jaari is a challenging subject. It’s about a woman who’s a salesgirl for condoms. In a country that still finds condom as a taboo word, I had to be very mindful to treat this subject delicately. I was walking a thin line. I didn’t want this film to be preachy but pass a good message at the same time. Didn’t want people to make fun of it but wanted to make this film entertaining too. But things eventually fell in place and I got the talented actress Nushrratt Bharuccha to work with who couldn’t be more right for this role. Even the rest of the cast was all very supportive. I really want this film to be a family entertainer and not a tv commercial people awkwardly move away from at homes.”
(Disclaimer: The above press release comes to you under an arrangement with NewsVoir India and this publication takes no editorial responsibility for the same)